Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY159 as a Single Agent and In Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

NCT04682431 is registered in ClinicalTrials.gov with Ikena Oncology as lead sponsor.

NCT NCT04682431
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04682431 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY159 as a Single Agent and In Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Lead sponsor
Ikena Oncology
Phase
Phase 1
Overall status
Terminated
Start date
November 10, 2020
Completion date
August 31, 2023
Enrollment
127 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, breast cancer, colorectal cancer, gastric adenocarcinoma, gynecologic cancer, head and neck cancer, lung adenocarcinoma, pancreatic cancer